AI in practice: 4 real-world use cases in health and life sciences
March 5, 2026 |
Artificial Intelligence (AI) is often discussed in broad terms, with promises of transformation at scale. In practice, however, its value is realized in far more specific ways – when it is applied to clearly defined challenges, embedded into existing workflows, and paired with deep domain expertise.
Across health and life sciences, organizations are moving beyond experimentation and focusing on how AI can support better decisions, more efficient operations, and clearer communication. At Inizio, these capabilities are central to how we drive Intelligent Commercialization™ – connecting data, insight, and expertise to help teams act with greater clarity and confidence. The following four use cases from across Inizio illustrate what that looks like in real-world settings – supporting operational performance, insight generation, engagement strategies, and strategic decision-making across the commercialization journey.
How did Inizio Engage scale call monitoring with AI-powered speech analytics?
Traditional call monitoring approaches often limit both scale and consistency, with only a small proportion of interactions reviewed and feedback delivered retrospectively. In this use case, Inizio Engage applied AI-powered speech analytics to analyze calls at scale, enabling patterns, risks, and performance indicators to be identified more efficiently and consistently across large volumes of interactions.
By automating the analysis of call content, our client was able to move beyond manual sampling and focus attention where it mattered most. The approach supported more targeted coaching and quality assurance, helping improve agent performance while maintaining oversight across a significantly broader set of calls.
How did Inizio Evoke turn digital insights into smarter HCP engagement with hematologic oncologists?
Engaging hematologic oncologists effectively requires a clear understanding of how they seek, consume, and respond to information. In this example, Inizio Evoke used Narratev™, a product in their Cognitev™ platform, to uncover real-world engagement behaviors, moving beyond surface-level metrics to identify patterns that could inform more relevant and timely interactions.
By translating these insights into practical recommendations, our client was able to align engagement strategies more closely with oncologists’ information needs and preferences. This helped support more focused decision-making and enabled engagement approaches that were better grounded in observable behavior rather than assumptions.
How did Inizio Ignite accelerate indication strategy in rare endocrine disorders?
Developing an effective indication strategy in rare endocrine disorders requires teams to assess a wide range of potential opportunities while balancing scientific feasibility, commercial considerations, and internal alignment. In this example, Inizio Ignite used AssetNav, part of their Navigator AI™ platform, to evaluate and prioritize potential indications, enabling more informed and objective strategic discussions.
By applying consistent criteria and integrating insights across functions, teams were able to narrow a broad set of possibilities into a focused, prioritized shortlist. This supported clearer decision-making, faster alignment, and a more repeatable approach to indication planning that could be applied beyond a single strategic exercise.
How did Inizio Medical elevate MSL performance with AI-enabled field intelligence?
Medical Science Liaisons (MSLs) generate vast amounts of valuable insight through their interactions with healthcare professionals, yet much of this intelligence can be difficult to capture, structure, and apply consistently. Inizio Medical built iON AI™ HCP Interact to help transform unstructured field insights into actionable intelligence that could be shared across medical and commercial teams.
By using AI to synthesize insights from MSL activity, organizations can surface emerging themes, identify unmet needs, and support more consistent scientific exchange. This enables MSLs to spend less time on manual reporting and more time on high-value engagement, with clearer visibility into field insights to inform strategy and planning.
Taking AI from potential to practice
The impact of AI is not defined by the technology alone, but by how it is applied to real challenges and real decisions. When paired with human expertise and grounded in strong data foundations, AI becomes a powerful enabler of more focused action and measurable progress.
Rather than replacing existing processes, each example shows AI working alongside teams – extending their ability to monitor, understand, and act at scale. This is how Inizio helps organizations drive Intelligent Commercialization™ – using platforms, products, and solutions to turn insight into action and complexity into clarity across the pharma lifecycle.
Discover how Intelligent Commercialization™ is built to deliver real-world results.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development
Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and...
Infographic: Therapy Watch Acute Myeloid Leukemia market snapshot
This Acute Myeloid Leukemia infographic offers a snapshot of the real-world patient insights collected by our Therapy Watch study, based on data collected from a panel of 220 physicians across...
Navigating the future of AI: Insights from EphMRA’s one day meeting in London
Authored by: Ellie Forde and Mark Braund, Directors
Research conducted for Johnson and Johnson published in scientific journal
Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.
Connecting our Inizio Advisory capabilities to help a client address a threat to the brand, guide strategy and improve brand performance
The challenge Our client knew that prescribing of a key brand in a major market had slowed and needed to understand which patient segments were impacted so they could address...
Autoimmune conditions: Living With syndicated patient reports
The prevalence of autoimmune conditions is increasing, and despite significant advancements in treatments, individuals affected by these diseases may not be receiving the most effective management and care. In our...
How we elevated HCP market research engagement and insights using AI avatars for an immersive experience
Our client required an effective strategy for promoting discussions about self-paid vaccines with healthcare professionals (HCPs) during patient consultations. The conventional method of conducting market research would typically only deliver...
How we provided comprehensive real-world patient data for PAH using Therapy Watch, our syndicated market tracking solution
PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such...
The risk of replicating social bias in synthetic patient data – The need for human intelligence partnered with AI
Authored by Paul Reed and Anabelle Gall
Latest European developments and new talent at Research Partnership
Angela Duffy has been appointed as Managing Director for our European based ad hoc research teams. Angela has been an integral part of Research Partnership for 19 years, witnessing its...